- 500mg - Capecitabine.
Without a Prescription
Capecitabine is prescribed as a single agent for adjuvant treatment in patients with Dukes` C colon cancer who have undergone
complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. Capecitabine was non-inferior
to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Although neither Capecitabine nor combination chemotherapy
prolongs overall survival (OS), combination chemotherapy has been demonstrated to improve disease-free survival compared
to 5-FU/LV. Physicians should consider these results when prescribing single-agent Capecitabine in the adjuvant treatment of Dukes` C colon cancer.
Capecitabine is prescribed as first-line treatment of patients with metastatic colorectal carcinoma when treatment with
fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone.
A survival benefit over 5-FU/LV has not been demonstrated with Capecitabine monotherapy. Use of Capecitabine instead of 5-FU/LV
in combinations has not been adequately studied to assure safety or preservation of the survival advantage.
Capecitabine in combination with docetaxel is prescribed for the treatment of patients with metastatic breast cancer after
failure of prior anthracycline-containing chemotherapy.
Capecitabine monotherapy is also prescribed for the treatment of patients with metastatic breast cancer resistant to
both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further
anthracycline therapy is not prescribed, eg, patients who have received cumulative doses of 400 mg/m 2 of doxorubicin or
doxorubicin equivalents. Resistance is defined as progressive disease while on treatment, with or without an initial
response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant regimen.
Capecitabine recommended dosage of Capecitabine is 1250 mg/m 2 administered orally twice daily (morning and evening;
equivalent to 2500 mg/m 2 total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles.
Capecitabine tablets should be swallowed with water within 30 minutes after a meal. In combination with docetaxel, the
recommended dose of Capecitabine is 1250 mg/m 2 twice daily for 2 weeks followed by a 1-week rest period, combined with
docetaxel at 75 mg/m 2 as a 1-hour intravenous infusion every 3 weeks. Pre-medication, according to the docetaxel labeling,
should be started prior to docetaxel administration for patients receiving the Capecitabine plus docetaxel combination.
Adjuvant treatment in patients with Dukes` C colon cancer is recommended for a total of 6 months, ie,
Capecitabine 1250 mg/m 2 orally twice daily for 2 weeks followed by a 1-week rest period, given as 3-week cycles for a
total of 8 cycles (24 weeks).
Capecitabine is contraindicated in patients:
- with severe renal impairment (creatinine clearance below 30 mL/min [Cockroft and Gault]);
- with known dihydropyrimidine dehydrogenase (DPD) deficiency;
- who have a known hypersensitivity to 5-fluorouracil;
- with known hypersensitivity to Capecitabine or to any of its components;
Blister strip of 10 tablets.